

ORIGINAL ARTICLE

## Labour Induction With Randomized Comparison Of Oral And Intravaginal Misoprostol In Post Date Multigravida Women

Aqueela Ayaz<sup>1</sup>, Shazia Saeed<sup>2</sup>, Mian Usman Farooq<sup>3</sup>, Iftikhar Ahmad<sup>4</sup>, Muhammad Luqman Ali Bahoo<sup>5</sup>, Muhammad Saeed<sup>6</sup>

<sup>1</sup> Specialist Ob/Gyne, Hera General Hospital, Makkah, Kingdom of Saudi Arabia

<sup>2</sup> Senior Registrar Ob/Gyne, Bahawal Victoria Hospital, Bahawalpur, Pakistan

<sup>3</sup> Medical Research Officer, Hospital, Makkah, Kingdom of Saudi Arabia

<sup>4</sup> Consultant Pediatrics, Hospital, Makkah, Kingdom of Saudi Arabia

<sup>5</sup> Intern, Bahawal Victoria Hospital, Bahawalpur, Pakistan

<sup>6</sup> Consultant Radiologist, Al-Noor Specialist, Hospital, Makkah, Kingdom of Saudi Arabia

Submitted: 20 February 2007

Accepted: 3 December 2008

---

---

### Abstract

The efficacy and safety of oral versus vaginal misoprostol for elective induction of labor in post date multigravida with an unfavourable cervix was compared over a period of one year in the Bahawal Victoria Hospital, Bahawalpur, Pakistan. Eighty eight multigravida post date women were divided into two groups and given 50 mg misoprostol orally and 50 mg intravaginally, respectively. The induction to onset of significant uterine contractions and delivery intervals were lower in the first group (7.8 h vs. 8.9 h) when compared to (10.4 h vs. 12 h). The first group had a higher rate of Caesarean section (7% vs. 4%;  $p > 0.05$ ), uterine hyperstimulation (9% vs. 5%;  $p > 0.05$ ), uterine tachysystole (23% vs. 14%;  $p > 0.05$ ) and neonatal admissions to intensive care unit (12% vs. 4%;  $p > 0.05$ ) when compared to second group. Fifty mg oral misoprostol has the potential to induce labor as safely and effectively as the intravaginal route.

**Keywords:** Misoprostol, induction, labor, medical sciences

---

---

### Introduction

Lingering pregnancy is one of the most common indications of labour induction even though it has been carried out also for other indications of maternal and fetal origin and it has been done for approximately one in six pregnancies exceeding 24 weeks' gestation in the United States (1). Recent studies have suggested that by continuing pregnancy beyond 41 weeks, there is a statistically significant higher perinatal morbidity and mortality as well as an increased risk to the mother (2,3). Attempted induction with an unripe cervix is exigent and seldom results in success (4). Although many methods of preinduction cervical ripening have been anticipated but prostaglandins are the up to date agents of choice (5,6). Many evidences have highlighted the importance of prostaglandins for initiation and normal progress of labour (7) as well as to induce cervical ripening

and stimulate uterine contractions at a variety of doses and routes of administration i.e. orally or vaginally (8,9). Misoprostol have been compared satisfactorily with the presently agreed agent dinoprostone in cost and storage requirements. The most advantageous dosing regimen, timing, and route of administration lingered the focus of enduring research (10–12). Misoprostol is a reasonably priced synthetic prostaglandin E1 analogue (13), and its oral administration has obvious appeal because it offers ease and higher patient satisfactoriness and promises outpatient administration if proved safe and effective for cervical ripening and labour induction but it has been studied less comprehensively.

This study was a comparative analysis of the effectiveness and safety of oral misoprostol and intravaginal misoprostol for the use in the process of cervical ripening and inducing labour in multigravida post date pregnancies with a live fetus.

## Materials and Methods

This study was conducted from December 1, 2004 until November 30, 2005. Eighty women were selected for the study where 44 were randomized in the oral group (group A) and the remaining in the intravaginal group B. All of the women were recruited at Bahawal Victoria Hospital, Bahawalpur, Pakistan, a 1300 bedded tertiary referral center with an average annual delivery rate of 2500. The Hospital Research Committee approved the study and all participants gave their written informed consent after they had been made aware of the purpose of the study.

Inclusion criteria were those whose age were between 26-40 years, multigravida, accurate dating of gestation, singleton viable pregnancy, gestational age 40-42 weeks, cephalic presentation, unfavourable cervical status defined as a Bishop score (BS) of <6, intact membranes, patient's height more than 150 cm. Exclusion criteria were patients with known contraindications to receiving prostaglandins, placenta previa, previous uterine surgery and any antenatal complications (medical/obstetrical). The detailed history with general physical examination included vital signs and abdominal examination. A fetal cardiotocographic (CTG) trace to confirm fetal well-being was performed. Digital examination was done to confirm the BS. Baseline investigations included complete blood and urine examination, blood grouping and Rh factor were sent.

Gestational age was estimated by ultrasound biometry via Crown rump length (CRL) measurements in the first trimester of pregnancy in cases where there was more than 3 days difference from that obtained from the last menstrual period (LMP) (14). Uterine tachysystole was defined as >5 contractions of moderate to severe intensity per 10 minutes, uterine hypertonus as when one contraction lasted more than 2 minutes and hyperstimulation syndrome as the presence of non-reassuring FHR tracing combined with either tachysystole or hypertonus (15).

The patients were divided into group A and group B by randomization for induction with oral and vaginal misoprostol, respectively. The randomization was done by opening sequentially numbered opaque envelopes containing cards stating the drug for induction. Bishop's score was performed prior to administration of either preparation, if it was less than six; the patient was planned for induction of labour.

Misoprostol of 50 mcg tablet was given orally for induction in group A, and in group B induction was done by placing same dose high in posterior

fornix digitally, tablets were repeated after every four hours to a maximum of six doses if there was no uterine activity or if the uterine contractions were less than two mild contractions in ten minutes with the patient being comfortable. Fetal CTG was done to confirm fetal well-being before each dose.

When uterine activity suggested the onset of labour, vaginal assessment was performed and the women would be sent to the labour ward. During all the proceeding, maternal vitals were monitored at 4 hours interval. The time of dose introduction, beginning of significant uterine contractions (significant uterine contractions mean 3-5 contractions of moderate to severe intensity in 10 minutes) and delivery was noted. Adequate analgesia (pethidine) was given. Continuous fetal and maternal monitoring and progress of labor was recorded on partogram.

Failed induction of labour was defined as vaginal delivery not achieved within 24 hours of initiating induction of labour (16). The indications for Caesarean section (CS) were failed induction, maternal request after 24 hours of induction, uncontrolled hyper stimulation and fetal distress. The complications faced during induction procedure were recorded carefully and managed accordingly. Paediatrician was called to examine and resuscitate the baby at the time of delivery. Further management of neonates was done accordingly.

The primary outcome measures were time from induction to onset of significant uterine contractions and induction to delivery. The secondary outcomes were the CS rate, the incidence of uterine tachysystole, uterine hyperstimulation and fetal/neonatal complications.

Data were analyzed on SPSS and subjected to descriptive analysis. Z-Test: Two samples for mean were applied to numerical data (interval of induction to significant uterine contractions and delivery) while remaining categorical data was analyzed with Chi-squared test. P-value <0.05 was considered significant.

## Results

Mean age in group A was 34.3 as compared to 35.9 years in group B, while mean + standard deviation (SD) of gravidity was 3.6+1.6 in group A and 3.2+1.4 in group B respectively. On the other hand, mean + SD of parity in group A was 2.9+1.1 while group B had 2.4+0.9. In group A 13 subjects (30%) had active labor after insertion of single dose of misoprostol as compared to 12 (27%) in group B. The mean + standard error (SE) of induction to onset of significant uterine contractions interval

was 7.8 +0.6 hours in group A, while 8.9 + 0.5 hours in Group B (p>0.05). Similarly the mean induction to delivery interval was 10.4 + 0.8 hours in group A while 12 + 0.7 hours in group B (p>0.05). Failed induction was little bit less frequent in group A than group B (16% vs. 23%; p>0.05) (Table 1).

There were more subjects with uterine hyperstimulation and tachysystole in group A than group B i.e. (14% vs. 5%; p>0.05) and (23% vs. 14%; p>0.05) respectively but not statistically significant. Caesarean sections were performed in all subjects with uterine hyperstimulation syndrome in both groups. Meconium stained liquor was also found in four subjects in group A (Table 2). There were more neonatal admissions to intensive care unit in group A (12% vs. 5%; p>0.05). Perinatal death was noted in group B due to meconium aspiration syndrome (Table 3).

## Discussion

Interest in oral misoprostol for cervical ripening and labor induction is growing day by day (17-21). The present study was the one that compared oral misoprostol with intravaginal in such well homogenized groups. All of the women were multigravida with intact membranes and at more than forty weeks' gestation with no antenatal complications. Our rationale was to identify effectiveness and safety of oral misoprostol regimen with intravaginal regimen. We found that giving 50 mg of misoprostol every 4 hours was as effective and safe as vaginal administration of 50 mg doses every 4 hours, with no significant differences in maternal or neonatal outcomes. Although not statistically significant, in group A we found shorter mean intervals from start of induction to delivery and a higher propensity for vaginal delivery within 24 hours.

**Table 1 :** Obstetrical outcome

Variables		Group A n=44	Group B n=44	P - Value
Prostaglandin Doses For Active Labor	Single	13(30%)	12(27%)	NS‡
	Two	18(41%)	17(39%)	NS
	Three	6(14%)	8(18%)	NS
	Four	4(9%)	3(7%)	NS
	Five	3(7%)	4(9%)	NS
Interval (Mean ± SE†) (Hours)	Induction to Onset of SUC*	7.8 ± 0.6	8.9 ± 0.5	NS
	Induction to Vaginal Delivery	10.4 ± 0.8	12 ± 0.7	NS
Induction to Vaginal Delivery Interval Detail	<12 hours	20(45%)	18(41%)	NS
	12≥ to ≤24 hours	17(39%)	16(36%)	NS
Mode of Delivery (within 24 hours of induction)	Vaginal Delivery	37(84%)	34(77%)	NS
	C-Section	3(7%)	2(4%)	NS

\* Significant Uterine Contractions (3-5 moderate to severe contraction in 10 minutes)

† Standard Error

‡ Non Significant

**Table 2 :** Complications during cervical ripening

Variables	Group A n=44	Group B n=44	P - Value
Urine Hyper Stimulation	4(9%)	2(5%)	NS
Uterine Tachysystole	10(23%)	6(14%)	NS
Allergic Reaction	2(5%)	2(5%)	NS
Nausea and Vomitting	3(7%)	1(2%)	NS
Meconium Stained Liquor	4(9%)	2(5%)	NS

**Table 3 : Neonatal Outcome**

Variables		Group A n=44	Group B n=44	P - Value
Birth weight (g)*		2965 ± 430	3073 ± 390	NS
Perinatal death		0	1(2%)	NS
Ambo ventilation		5(11%)	2(5%)	NS
Intubations in labor room		3(7%)	1(2%)	NS
APGAR < 7	1 min	6(14%)	5(11%)	NS
	5 min	1(2%)	0	NS
ICU	Within 24 hours	2(5%)	1(2%)	NS
Admissions	After 24 hours	3(7%)	1(2%)	NS

\*Values expressed as mean ± SD

In previous studies, 50 mg of oral misoprostol given every 4 hours was associated with longer intervals to delivery compared with vaginal misoprostol (13, 20). In one Egyptian research, 100 mg of oral misoprostol was administered to 20 subjects, then doubled the dose after 3 hours if there was inadequate clinical response. They compared that regimen with repeated doses of 100 mg of vaginal misoprostol and found greater efficacy but more fetal heart rate and uterine contraction abnormalities with vaginal administration (19).

In our investigation, uterine contractile abnormalities were more frequent in women treated with oral misoprostol, although the abnormalities did not differ significantly from those of women who received vaginal misoprostol. Less than 15% of women who received vaginal misoprostol had tachysystole, which is lower incidence in our experience as in other studies (22-24). The relatively long half-life of misoprostol and its metabolites in maternal serum after vaginal administration also might account for delayed tachysystole in women than those who received the medication orally (14).

On the other hand, if we took into account the neonatal outcome, the oral dose was associated with a higher chance of admittance to the neonatal intensive care unit but this was not statistically significant.

Our limited data supported the use of 50 mg doses of oral misoprostol for preinduction cervical ripening and labor initiation because it had almost same efficacy and safety as its vaginal analogue. Oral route approach offered convenience, higher patient acceptance, ease of administration, and reduction of nursing interventions.

In order to clarify the aforesaid side effects of misoprostol use, it appeared that the adverse

effects were not only misoprostol-related but it may be dose as well as dose interval dependent and probably has a large inter-patient variability in terms of pharmacokinetics.

### Conclusion

Our results indicated that, in a closely supervised hospital setting with adequate monitoring, 50mg oral misoprostol has the potential to induce labor as safely and effectively as its vaginal route. Additional research is needed to categorically determine the most effective dosing regimens and intervals. We also believe further studies on safety with larger numbers of women need to be conducted before we advocate routine oral misoprostol.

### Correspondence

Dr. Mian Usman Farooq  
 MBBS(Nishtar Medical College, Multan, Pakistan)  
 Medical Research Officer, Health Research Centre  
 Al-Noor Specialist Hospital  
 P.O. Box 6251 Holy Makkah, Saudi Arabia  
 Tel: + 00966568232502  
 Fax: + 0096625664393  
 Email: drus76@yahoo.com

## References

1. Ventura SJ, Martin JA, Curtin SC, Mathews TJ. Births: Final data for 1997. National Center for Health Statistics. *National Vital Statistics Reports*, 1999; **47**: 1–96.
2. Hilder L, Costeloe K, Thilaganathan B. Prolonged pregnancy. Evaluating gestation-specific risks of fetal and infant mortality. *Br J Obstet Gynaecol* 1998; **105(2)**: 169–173.
3. Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis. *BMJ* 1999; **319(7205)**: 287–298.
4. Bishop EH. Pelvic scoring for elective induction of labor. *Obstet Gynecol* 1964; **24**: 266–8.
5. Sanchez-Ramos L, Kaldnitz AM, Conner P. Hydroscopic cervical dilatation of the cervix. A comparison with PGE<sub>2</sub> gel. *J Reprod Med* 1992; **37**:355–9.
6. Xenakis EM-J, Piper JM, Conway DL, Langer O. Induction of labor in the nineties: Conquering the unfavorable cervix. *Obstet Gynecol* 1997; **90**: 235–9.
7. Bleasdale JE, Johnstone JM. Prostaglandin and human parturition. Regulation of arachidonic acid and mobilization. *Rev Perinatal Med* 1984; **5**: 154–91.
8. O'Brian WF. Cervical ripening and labour induction: progress and challenges. *Clin Obstet Gynaecol* 1995; **38**: 89–100.
9. Keirse MJ. Prostaglandin in preinduction cervical ripening: meta analysis of worldwide clinical experience. *J Reprod Med* 1993; **38**: 89–100.
10. Wing DA, Paul RH. A comparison of different dosing regimens of vaginally administered misoprostol for preinduction cervical ripening and labor induction. *Am J Obstet Gynecol* 1996; **175**: 158–64.
11. Sanchez-Ramos L, Kaunitz AM, Wears RL, Delke I, Gaudier FL. Misoprostol for cervical ripening and labor induction: A meta-analysis. *Obstet Gynecol* 1997; **89**:633–42.
12. Farah LA, Sanchez-Ramos L, Rosa C, Del Valle GO, Gaudier FL, Delke I, et al. Randomized trial of two doses of the prostaglandin E<sub>1</sub> analog misoprostol for labor induction. *Am J Obstet Gynecol* 1997; **177**: 364–71.
13. Garris RE, Kirkwood CF. Misoprostol: A prostaglandin E<sub>1</sub> analogue. *Clin Pharm* 1989; **8**: 627–44.
14. Goldstein SR. Embryonic ultrasonographic measurements: crown-rump length revisited. *Am J Obstet Gynecol* 1991; **165**: 497–501.
15. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no 207. Washington, DC: American College of Obstetricians and Gynecologists; 1995. Fetal heart rate patterns: monitoring, interpretation, and management.
16. Kelly A, Alfrevic Z, Hofmeyr GJ, Kavanagh J, Neilson JP, Thomas J. Induction of labour in specific clinical situations: generic protocol (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, 2004.
17. Ngai SW, To WK, Lao T, Ho PC. Cervical priming with oral misoprostol in pre-labor rupture of membranes at term. *Obstet Gynecol* 1996; **87**: 923–6.
18. Windrim R, Bennett K, Mundle W, Young DC. Oral administration of misoprostol for labor induction: A randomized controlled trial. *Obstet Gynecol* 1997; **89**:392–7.
19. Topozada MK, Anwar MYM, Hassan HA, El-Gazaerly WS. Oral or vaginal misoprostol for induction of labor. *Int J Gynaecol Obstet* 1997; **56**: 135–9.
20. Bennett DA, Butt K, Crane JMG, Hutchens D, Young DC. A masked randomized comparison of oral and vaginal administration of misoprostol for labor induction. *Obstet Gynecol* 1998; **92**: 481–6.
21. Adair CD, Weeks JW, Barrilleaux S, Edwards M, Burlison K, Lewis DF. Oral or vaginal misoprostol administration for induction of labor: A randomized, double-blind trial. *Obstet Gynecol* 1998; **92**: 810–3.
22. Wing DA, Jones MM, Rahall A, Goodwin TM, Paul RH. A comparison of misoprostol and prostaglandin E<sub>2</sub> gel for preinduction cervical ripening and labor induction. *Am J Obstet Gynecol* 1995; **172**: 1804–10.
23. Wing DA, Paul RH. A comparison of differing dosing regimens of vaginally administered misoprostol for preinduction cervical ripening and labor induction. *Am J Obstet Gynecol* 1996; **175**: 158–64.
24. Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. *Am J Obstet Gynecol* 1997; **177**: 612–8.
25. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. *Obstet Gynecol* 1997; **90**: 88–92.